New drug indication approval - January 2023

Product Name

CABOMETYX FILM COATED TABLET 20MG, 40MG AND 60MG

Active Ingredient

Cabozantinib

Product Registrant

IPSEN PHARMA SINGAPORE PTE. LTD.

Date of Approval

05/01/2023

Indications:

CABOMETYX is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to radioactive iodine (RAI) who have progressed during or after prior systemic therapy.

Product Name

POLIVY POWDER FOR CONCENTRATION FOR SOLUTION FOR INFUSION 30MG AND 140MG

Active Ingredient

Polatuzumab

Product Registrant

ROCHE SINGAPORE PTE LTD

Date of Approval

13/01/2023

Indications:

Polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).